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Abstract
Background
After cardiac surgery with cardiopulmonary bypass (CPB), acquired coagulopathy often
leads to post-CPB bleeding. Though multifactorial in origin, this coagulopathy is often ag-
gravated by deficient fibrinogen levels.
Objective
To assess whether laboratory and thrombelastometric testing on CPB can predict plasma fi-
brinogen immediately after CPB weaning.
Patients / Methods
This prospective study in 110 patients undergoing major cardiovascular surgery at risk of
post-CPB bleeding compares fibrinogen level (Clauss method) and function (fibrin-specific
thrombelastometry) in order to study the predictability of their course early after termination
of CPB. Linear regression analysis and receiver operating characteristics were used to de-
termine correlations and predictive accuracy.
Results
Quantitative estimation of post-CPB Clauss fibrinogen from on-CPB fibrinogen was feasible
with small bias (+0.19 g/l), but with poor precision and a percentage of error >30%. A clini-
cally useful alternative approach was developed by using on-CPB A10 to predict a Clauss fi-
brinogen range of interest instead of a discrete level. An on-CPB A1010 mm identified
patients with a post-CPB Clauss fibrinogen of1.5 g/l with a sensitivity of 0.99 and a posi-
tive predictive value of 0.60; it also identified those without a post-CPB Clauss fibrinogen
<2.0 g/l with a specificity of 0.83.
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Conclusions
When measured on CPB prior to weaning, a FIBTEM A1010 mm is an early alert for post-
CPB fibrinogen levels below or within the substitution range (1.5–2.0 g/l) recommended in
case of post-CPB coagulopathic bleeding. This helps to minimize the delay to data-based
hemostatic management after weaning from CPB.
Introduction
Platelet aggregation and hemostatic clot formation are strongly associated with the presence of
fibrinogen, a soluble glycoprotein upregulated in a variety of inflammatory conditions.[1–3]
Recently, fibrinogen gained renewed clinical interest after a number of studies demonstrated
the inverse relationship between fibrinogen levels, perioperative blood loss and exposure to al-
logeneic blood transfusion.[1–9] In cardiac surgery with cardiopulmonary bypass (CPB),
major post-CPB bleeding is not infrequent since CPB-associated conditions (e.g., hemodilu-
tion, hypothermia, platelet dysfunction and fibrinolysis) impair fibrinogen levels, function and
hence, clot stability. This multifactorial acquired coagulopathy increases bleeding, allogeneic
blood product exposure, morbidity and mortality.[5,10–15] Current European guidelines rec-
ommend fibrinogen substitution as a first-line therapy in case of significant bleeding accompa-
nied by low levels of plasma fibrinogen.[16,17]
Plasma fibrinogen level is traditionally determined by time-consuming direct measurement
(clottable fibrinogen according to the technique by Clauss). More recently, in a point-of-care
setting and much faster, thrombelastometry (ROTEM) is used to quantify fibrin-dependent
clot firmness (FIBTEM assay). It has been advocated that point-of-care thrombelastometry can
be used to replace the Clauss method under perioperative conditions, not only due to its more
comprehensive representation of functional fibrinogen potential, but also for its much shorter
turnaround time.[18–20] Current guidelines recommend fibrinogen substitution if substantial
bleeding is accompanied by a plasma fibrinogen of less than 1.5 to 2.0 g/l.[21–24] Selection of a
clinically appropriate substitution threshold and target range, and accurate as well as rapid de-
termination of fibrinogen status around these points are needed for efficacious and safe hemo-
static management. Undersubstitution, treatment delays or oversubstitution are all likely to
increase complication rate. Undersubstitution will fail to normalize clinical coagulation in due
time, resulting in continued blood loss, prolonged hemodynamic instability, difficult surgical
hemostasis and exposure to repetitive transfusion rounds. Abnormally high fibrinogen levels,
e.g. in the range commonly observed beyond the second postoperative day, are an independent
risk factor for thrombosis, stroke and myocardial infarction.[9,25–27]
We hypothesized that analysis of fibrinogen level and function during CPB prior to weaning
provides early and reliable information for the immediate post-weaning diagnosis and treatment
of hypofibrinemic bleeding. The aim of our study was to compare Clauss fibrinogen levels and si-
multaneously sampled FIBTEM assays during rewarming prior to CPB weaning as well as after
weaning and heparin reversal, and to assess discriminatory power of FIBTEM parameters for
post-CPB fibrinogen substitution thresholds recommended by current guidelines [24,28].
Materials and Methods
Study Design and Patient Cohort
This is a prospective observational study of sequential coagulation analysis during cardiovascu-
lar surgery on CPB. Consecutive patients undergoing a prospectively defined variety of
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cardiovascular procedures with moderate to high bleeding risk, according to the study of Kar-
kouti et al.,[29] were included, with the aim to provide external validity for a patient population
of an academic cardiac center: combined coronary and valve surgery, re-do cardiac surgery,
cardiac transplantation, left ventricular assist device implantation, use of hypothermic circula-
tory arrest, thoracic or thoracoabdominal aortic repair, or with other predictors of increased
post-CPB bleeding risk (active dual antiplatelet therapy, liver insufficiency, prolonged CPB
runs>120 min). All procedures were performed at the University Hospital Bern, Switzerland,
between June 2009 and July 2011.
Since acquisition of ROTEM analysis by our hospital in 2009, institutional policy of the De-
partment of Hematology and Central Hematology Laboratory stipulated availability of sequen-
tial, and simultaneously sampled, conventional and thrombelastometric coagulation test
results prior to the release of factor concentrates to operating room teams. In order to reduce
laboratory expense in the future, these datasets were analyzed for clinically useful correlations
and predictive power. All patients undergoing cardiovascular procedures on CPB as mentioned
above were screened for the study. Exclusion criteria were unpaired conventional and FIBTEM
samples, or exogenous substitution with fibrinogen concentrate during the study period, i.e.,
pre-, on, and post-CPB until transfer to the intensive care unit (ICU).
Ethical approval for the study (registration number 197/08) was provided by the Cantonal
Ethics Committee (Kantonale Ethikkommission Bern, Postfach 56, 3010 Bern. Contact: Dr. sc.
nat. Dorothy Pfiffner). All patients gave written informed consent for pertinent laboratory
analysis and blood product substitution, and for use of their anonymized data for research pur-
poses. The STROBE checklist for observational studies was used to guide the methods and to
structure this manuscript.[30]
Anesthesia, CPB and Management of Hemostasis
All patients received general anesthesia and cardiovascular surgery according to institutional
standards. Anesthetic monitoring included American Society of Anesthesiologists standard
monitoring, invasive blood pressure, central venous pressure, urine output and nasopharyngeal
temperature monitoring. Depending on the procedure, cardiac surgery was performed using
either conventional extracorporeal circulation (CECC; Maquet Holding, Germany; 88% of the
patients) primed with 500 ml hydroxyethyl starch (130/0.4), 1000 ml Ringer´s solution, 100 ml
of 20% mannitol and 10.000 IU heparin, or a minimized extracorporeal circuit (MECC; Med-
tronic, Minneapolis, USA; 12% of the patients) primed with 600 ml Ringer´s solution and 5000
IU heparin. No heparin-coated components were used. Routine antifibrinolytic treatment con-
sisted of tranexamic acid (loading dose, 30 mg/kg over 30 min after heparin administration fol-
lowed by 15 mg/kg/h until skin closure). Myocardial protection was provided with a single
dose of 100 ml antegrade crystalloid cardioplegia (Cardioplex, Bichsel AG, Interlaken, Switzer-
land), and in the case of prolonged bypass time, with additional high-potassium cold blood car-
dioplegia (Buckberg Solution, Bichsel AG., Interlaken, Switzerland) repeated every 20–30
minutes. A bolus of heparin was given (CECC: 500 IU kg-1; MECC: 400 IU kg-1) prior to aortic
cannulation to achieve a target kaolin-activated clotting time (high-range ACT) of>480 sec-
onds (Activated Coagulation Timer ACT II, Medtronic, Minneapolis, USA) before starting car-
diopulmonary bypass. On CECC during full anticoagulation, shed blood was filtered and
reinfused via the cardiotomy reservoir into the CPB circuit, or underwent autologous cell sal-
vage, red blood cell separation, processing and reinfusion pre- and post-heparinization. With
MECC, shed blood was entirely salvaged using an optoelectrical sensor suction device
(SMART, Fumedica AG., Muri, Switzerland), which is activated only when in direct contact
with liquid; here, all suctioned blood was first processed using a cell-saving device and then
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reinfused. After weaning from CPB, heparin was reversed with protamine in a ratio of 1:1 with
regard to the initial heparin bolus. A post-reversal ACT of<130 seconds was targeted.
Intraoperative coagulation testing was performed from venous blood sampled from a cen-
tral venous line or from the extracorporeal circuit and sent by pneumatic tube transport to the
central hematology laboratory for complete blood count, international normalized ratio, fibrin-
ogen concentration (Clauss method) and simultaneous thrombelastometry (ROTEM delta,
Axon Lab, Switzerland). To account for our laboratory´s turnover time of 45 min for conven-
tional coagulation testing, samples were obtained 30–40 min prior to the projected termination
of CPB (on-CPB), and again after full heparin reversal with protamine (post-CPB). Choice and
amount of transfused allogeneic blood products were left to the discretion of the attending
anesthesiologist and intensivist, respectively, within the limits of our institutional transfusion
guidelines. Fresh frozen plasma, which contains fibrinogen, was only given after obtaining
blood for the post-CPB measurement time point.
Measurement of Plasma Fibrinogen
Plasma levels of fibrinogen were measured using the Clauss technique on a commercially avail-
able coagulation analyzer (BCS, Dade Behring Inc., Germany) using the Multifibren U-Reagent
according to manufacturer`s specifications and pertinent publications.[31] Briefly, excess
thrombin added to diluted and recalcified citrated plasma converts fibrinogen into fibrin
monomers, which spontaneously polymerize into a clot. The time needed for clot formation is
inversely correlated with the plasma fibrinogen, which is calculated using a calibration curve.
Sequential analysis using thrombelastometry included assays for INTEM, EXTEM, FIBTEM
and HEPTEM. Briefly, native or—as in our study—recalcified citrated whole blood (300 μl) is im-
mersed into a heated cuvette with an oscillating pin suspended in the blood sample. Rotation of the
pin back and forth through an angle of 4°75`in the center of the cuvette initiates platelet activation
and fibrin polymerization, which in turn increases torque and progressively restricts pin move-
ment. The viscoelastic change is transmitted for signal processing and graphical display via an opti-
cal detector system composed of a light source with a mirror mounted on axis. [32,33] In FIBTEM,
tissue factor is used as activator with cytochalasin D added for platelet inhibition, which provides a
measure of net fibrinogen polymerization. Although all ROTEM variables were recorded, compar-
ative analysis in this study focuses on clot formation amplitude at 10 min (A10) and maximum
clot firmness (MCF). Reference range was 9–24 mm for A10 and 8–25 mm for MCF.[34] In order
to ensure quality control and to minimize user-dependent variability, all coagulation and thrombe-
lastometry analyses were performed in our central hematology lab at an analysis temperature of
37°C by certified bioanalytical technicians. Pre-analytical workup, parameters and real-time display
of results in the operating room have been described previously.[19,32,35–37]
Data Collection and Statistical Analyses
Demographic data and intraoperative variables were collected in a prospective observational
fashion. Clauss fibrinogen and ROTEM results were stored in and retrieved from the laborato-
ry´s data base system. Analysis time stamps were linked to CPB time stamps, comparing simul-
taneously acquired Clauss fibrinogen and FIBTEM results sampled prior to (pre-CPB), during
(on-CPB) and after CPB (post-CPB).
Linear regression analysis was used to assess the relationship between Clauss fibrinogen and
FIBTEM variables, or between different times of measurement using the Pearson product-mo-
ment correlation coefficient (Pearson´s r). Methods were compared using mean difference
(bias), the standard deviation of the difference and the limits of agreement (bias ± 1.96 x stan-
dard deviations), also expressed as the percentage of error (= 100 x 1.96 x standard deviation of
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the difference between the post-CPB and the on-CPB value / mean of on-CPB and post-CPB
value). Receiver operating characteristics (ROC) analysis was used to assess diagnostic or pre-
dictive power of FIBTEM and fibrinogen data.
Data are presented as counts (percentage), mean ± standard deviation, median with inter-
quartile ranges [25q;75q], regression coefficient (r) and area under the curve for ROC (AUC)
as appropriate. A p-value of<0.05 was considered statistically significant. For statistical analy-
sis we used SigmaPlot for Windows, Version 10.0 and SigmaStat for Windows, Version 3.0
(Systat Software, Inc., Germany).
Results
Procedural and Outcome Data
Of 2232 CPB procedures in the observation period, 110 patients had paired conventional and
FIBTEM samples, and did not receive exogenous substitution with fibrinogen concentrate dur-
ing the study period, i.e., pre-, on, and post-CPB until transfer to the intensive care unit (ICU).
Demographics and preoperative anticoagulant medication are given in Table 1.
Table 2 lists procedural data pertinent to perioperative fibrinogen kinetics, and basic out-
comes. In this cohort with moderate to high bleeding risk and prolonged duration of CPB,
Clauss fibrinogen levels below the institutional lower reference limit (1.75 g/l) were observed in
29% of included patients during CPB, and in 19% after CPB weaning. Allogeneic product
transfusion in exposed patients after weaning from CPB until transfer to the ICU were 4 [2;6]
units of red blood cells and 4 [2;6] units of fresh frozen plasma (Table 2). Overall perioperative
exposure to any allogeneic blood product transfusion was 86% (95 / 110).
During ICU stay, cumulative postoperative chest tube drainage volume was 820 [90;26890]
ml. Six patients (5%) required surgical re-exploration due to excessive postoperative bleeding
in the ICU. Length of ICU stay was 1 [1;3] days, with readiness for hospital discharge after 12
[8;18] days. Infective and thromboembolic events occurred in 24 (22) and 11 (10) patients, re-
spectively. In-hospital mortality was 10% (11 / 110).
Changes of Clauss Fibrinogen and FIBTEM in Relation to CPB
Clauss fibrinogen level and A10 amplitude were highest pre-CPB (fibrinogen, 3.9 ± 1.8 g/l;
A10, 18.2 ± 7.1 mm; MCF, 20.1 ± 8.1 mm). On CPB prior to weaning, a significant decrease
Table 1. Patients`demographics and preoperative antithrombotic medication.
Age, years 62 ± 14
Female sex 31 (28)
BMI, kg/m2 41 ± 4
EuroScore, additive 7 ± 3
Ejection fraction, % 55 ± 14
Pre-operative antithrombotics
Acetylsalicylic acid 50 (45)
Warfarin 24 (22)
Clopidogrel 14 (13)
Heparin 12 (11)
Nadroparin 8 (7)
Tiroﬁban 1 (1)
Prasugrel 1 (1)
BMI indicates body mass index. Data are numbers (percent), mean ± standard deviation or median with
interquartile ranges [25q;75q] where appropriate.
doi:10.1371/journal.pone.0126692.t001
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Table 2. Procedural data.
Procedure
Isolated CABG 13 (12)
Valve surgery and CABG 39 (35)
Thoracic aorta repair 27 (25)
Thoracoabdominal aorta repair 21 (19)
Heart transplantation and LVAD 10 (9)
Re-do surgery 34 (31)
Emergency surgery 10 (9)
Duration of surgery, min 281 [62;890]
CPB time, min 137 [21;507]
Minimal temperature, Celsius 32 [20;37]
Fluids, coagulants, anticoagulants and transfusion
RBC concentrate, units 4 [2;6]
Patients exposed to RBC 78 (71)
AWRC, ml 560 [453;696]
Patients exposed to AWRC 77 (70)
FFP, U 4 [2;6]
Patients exposed to FFP 52 (47)
PC, U 2 [1;2]
Patients exposed to PC 60 (55)
PCC, U 11 [1125;1950]
Patients exposed to PCC 10 (9)
Fibrinogen concentrate, g 0 [0;0]
Patients exposed to ﬁbrinogen concentrate 0 (0)
Colloids, ml 0 [0;2100]
Postprocedural chest tube drainage, ml
After 12h 420 [60;4450]
After 24h 700 [90;5335]
After 48h 800 [90;8010]
Total in ICU 820 [90;26890]
Outcome and complications
ICU stay, d 1 [1;3]
Extubation, d 1 [0;1]
Hospital discharge, d 12 [8;18]
In-Hospital
Mortality 11 (10)
Infection 24 (22)
Thromboembolism 11 (10)
Bleeding requiring reexploration 6 (5)
CABG indicates coronary artery bypass grafting; LVAD, left ventricular assist device; CPB,
cardiopulmonary bypass; RBC, red blood cell; AWRC, autologous washed red cells; FFP, fresh frozen
plasma; PC, platelet concentrate; PCC, prothrombin complex concentrate; ICU, intensive care unit; d, days;
h, hours; U, units (1 unit corresponds to 250–275 ml). Data are numbers (percent), mean ± standard
deviation or median with interquartile ranges [25q;75q] where appropriate.
doi:10.1371/journal.pone.0126692.t002
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was apparent (fibrinogen, 2.1 ± 0.9 g/l; A10, 10.2 ± 5.4 mm; MCF, 11.5 ± 6.5 mm), without sig-
nificant difference to levels early after CPB and heparin reversal (fibrinogen, 2.1 ± 0.8 g/l; A10,
9.7 ± 4.9 mm; MCF, 10.9 ± 5.7 mm) (Fig 1).
Correlation and Discriminatory Power of Fibrinogen and FIBTEM
Clauss fibrinogen and A10 were significantly correlated (all data points, r = 0.81; p<0.05).
Their correlation was closer on-CPB at a mean Hb of 83 g/l (r = 0.87) and post-CPB (mean Hb
88 g/l; r = 0.74) than pre-CPB (mean Hb 105 g/l; r = 0.66) (Fig 2).
The discriminatory power of A10 and MCF for various assumed fibrinogen substitution
thresholds was determined for fibrinogen cutoffs between 1.0 and 2.2 g/l. ROC analysis showed
that FIBTEM discrimination of fibrinogen cutoffs in this range was generally good with some
variability (A10, ROC-AUC 0.91 to 0.95; MCF, 0.90 to 0.95 (Fig 3)). For cutoffs between 1.5 g/l
and 2.0 g/l, which reflect current recommendations for perioperative fibrinogen substitution
[9,16,22,38], the discriminatory power of the more rapid A10 result was not inferior to MCF.
Sensitivity and specificity of A10 were balanced best at 7.5 mm, offering an even better maxi-
mum sensitivity (0.89) and specificity (0.88) for a fibrinogen cutoff at 1.6 g/l than MCF (Fig 3).
Within-Test Correlation between On-CPB and Post-CPB Fibrinogen and
FIBTEM
The difference between on-CPB and post-CPB results for Clauss fibrinogen, A10, or MCF was
not significant (Fig 1). Although comparison of measurements also demonstrated close within-
test correlation (r> 0.87) and small bias, precision was low and percentage of error was>30%
for Clauss fibrinogen, A10 and MCF (Table 3, Fig 4).
On-CPB FIBTEM to Predict post-CPB Fibrinogen Substitution Range
ROC analysis showed that a Clauss fibrinogen level1.5 g/l is to be expected post-CPB when
A10 is below 6.9 mm on-CPB (both sensitivity and specificity = 0.87). Likewise, a post-CPB
Fig 1. Clauss fibrinogen and A10 in relation to CPB. Boxplot, median, 25th/75th percentile; whiskers, 10th/90th percentile; extremes. A10, A10. *) denotes
significant (p < 0.05) change between times of measurement.
doi:10.1371/journal.pone.0126692.g001
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fibrinogen>2.0 g/l is likely when on-CPB A10 amplitude is above 9.0 mm (both sensitivity
and specificity = 0.88) (black circles, Fig 5).
This diagnostic accuracy, however, is still less than satisfactory. For clinical purposes, it is
more helpful to rapidly pre-identify all patients with low fibrinogen post-CPB (i.e., aiming for
high sensitivity of A10 on-CPB for post-CPB fibrinogen1.5 g/l). On the other hand, exoge-
nous fibrinogen administration appears unreasonable at post-CPB fibrinogen levels2.0 g/l.
Thus, on-CPB prediction using A10 should aim for high specificity for post-CPB fibrinogen
<2.0 g/l. These two clinically relevant conditions were fulfilled best at an on-CPB A10 of 10
mm, with sensitivity (lower border of substitution range) at 0.99, and specificity (upper border)
at 0.83, respectively (Fig 5). This on-CPB A10 amplitude had a positive predictive value (PPV)
of 0.60 for post-CPB fibrinogen 1.5 g/l and a negative predictive value (NPV) of 0.92 for
post-CPB fibrinogen<2.0 g/l.
Intraoperative Allogeneic Blood Product Use and Postoperative
Drainage Loss
Post-CPB fibrinogen assessment was followed by significant use of fresh frozen plasma, plate-
lets and an overall high exposure to allogeneic transfusion in our study population (Table 2).
Subsets of patients with on-CPB A1010 mm and A10>10 mm in the post-CPB period did
Fig 2. Relationship between Clauss fibrinogen and A10 according to operative period andmean hemoglobin.Regression analysis. Equation:
Polynomial, linear. Blue lines = 95%Confidence Band; Red lines = 95% Prediction Band. A10, A10.
doi:10.1371/journal.pone.0126692.g002
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not show statistically significant difference for transfusion of any blood product (p values for
red blood cells = 0.35; fresh frozen plasma = 0.07; platelet concentrate = 0.19) or for chest tube
loss (after 24 hours: p = 0.34).
Discussion
This observational study tracked conventional and thrombelastometric fibrinogen status on
weaning from CPB in a representative cohort undergoing major cardiovascular surgery. Its
main findings were as follows:
In accordance with the current rationale for thrombelastometry in suspected hypofibrino-
genemic post-CPB bleeding, FIBTEM A10 and MCF correlate with plasma fibrinogen (Clauss).
This is more marked with hemodilution, as has been described before [39]. FIBTEM A10 is
more rapidly available, and discriminates equally well or better than MCF in the range of clini-
cal interest between 1.5 g/l and 2.0 g/l plasma fibrinogen. Also, pre-weaning and post-CPB
Fig 3. Discriminative power of FIBTEM variables for Clauss fibrinogen (A) and ROC curves at Clauss fibrinogen cutoff of 1.6 g/l (B). Red
arrow = highest ROC-AUC in the recommended range for fibrinogen substitution by guidelines (blue transparent square). ROC, receiver
operating characteristics.
doi:10.1371/journal.pone.0126692.g003
Table 3. Percentage of error calculation.
Clauss ﬁbrinogen (g/l) FIBTEM A10 (mm) FIBTEM MCF (mm)
Bias 0.19 - 0.42 - 0.29
Standard deviation 0.43 2.67 2.59
Limits of agreement -0.66, 1.04 -5.64, 4.81 -5.38, 4.79
Bias 95% of conﬁdence interval 0.01–0.37 -1.55–0.71 -1.39–0.81
Percentage of error, % 41.3 53.2 45.3
Percentage of error = 100 x 1.96 x standard deviation of the difference between the post-CPB and the on-CPB value / mean of on-CPB and post-
CPB value.
doi:10.1371/journal.pone.0126692.t003
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results of both techniques are closely correlated, which can be used for planning of post-CPB
hemostatic management. Despite such significant correlations, however, there is considerable
imprecision both in FIBTEM-based fibrinogen estimates and in prediction of post-CPB values
from pre-weaning data. By choosing a categorical approach instead, we found that FIBTEM
A10, when sampled on CPB prior to weaning, allows accurate and clinically useful identifica-
tion of patients who will be in- or outside a target zone of 1.5–2.0 g/l plasma fibrinogen after
weaning and heparin reversal.
Our findings of correlations between conventional and point-of-care fibrinogen test meth-
ods are confirmative of current literature for a large and clinically representative variety of
major cardiovascular surgery.[32,40,41] However, even if Clauss fibrinogen and FIBTEM cor-
relate with each other, and also show close within-test correlation and small bias, the limits of
agreement between on-CPB and post-CPB samples are wide. An exact prediction of the latter,
e.g., by using linear regression equations of Fig 4, is thus not possible. Therefore we chose a cat-
egorical approach [42], classifying predicted post-CPB fibrinogen into three clinically relevant
zones of a) hypofibrinogenemia1.5 g/l, b) a target range of 1.6–2.0 g/l, and c) fibrinogen
>2.0 g/l. We identified an optimal operating point at an A10 of 10 mm, measured on-CPB
prior to weaning. This decision threshold provides a sensitivity of 0.99 for ruling in a post-CPB
fibrinogen1.5 g/l (Clauss method). Thus, in case of non-surgical bleeding after heparin
Fig 4. Relationship and correlation estimates between on-CPB and post-CPB levels of Clauss fibrinogen (A), A10 (B) and MCF (C) with
corresponding Bland-Altman plot.CPB, cardiopulmonary bypass; FIBTEM A10, A10; MCF, maximum clot firmness.
doi:10.1371/journal.pone.0126692.g004
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reversal, such information is already at hand for triggering fibrinogen substitution towards the
target range of 1.5–2.0 g/l.[9,16,22,38] The same threshold allows on CPB to rule out a post-
CPB fibrinogen>2.0 g/l with a specificity of 0.83, in order to minimize oversubstitution in con-
junction with clinical assessment of bleeding. A lower diagnostic resolution of on-CPB A10 for
fibrinogen cutoff at 1.5 g/l (positive predictive value 0.60) appears clinically acceptable in view
of the lack of safety signals for fibrinogen replacement (with FFP or factor concentrate) at levels
below 2.0 g/l.[43] With this approach, and regardless of whether conventional or point-of-care
testing is the preferred institutional routine, on-CPB sampling during rewarming enables the
clinician to plan post-CPB fibrinogen management in a timely and simple fashion. Thus early
diagnosis and immediate, data-driven treatment of hypofibrinogenemic bleeding after termi-
nation of CPB is feasible.
Our study, although observational and from a single institution, has external validity since it
analyses a mixed cohort of patients undergoing major cardiovascular surgery at risk of post-
CPB bleeding, transfusion and mortality, and without exogenously administered fibrinogen
concentrate.
Fig 5. Sensitivity and specificity of A10 for Clauss fibrinogen limits of 1.5 and 2.0 g/l, respectively, with optimal operating point at 10 mm (A10).
Two-graph fitted ROC curves with 95% confidence interval showing sensitivity and specificity for each limit. Sensitivity (blue curve) and specificity (gray dash-
dot curve) for post-CPB Clauss fibrinogen1.5 g/l and sensitivity (gray dash-dot-dot curve) and specificity (green curve) for post-CPB Clauss fibrinogen
>2.0 g/l. Black circles: best sensitivity and specificity for Clauss fibrinogen1.5 g/l (left circle, corresponds to A10 of 6.9 mm) and for Clauss fibrinogen
>2.0 g/l (right circle, corresponds to A10 of 9.0). Red cross corresponds to optimal operating point with an on-CPB A10 sensitivity for post-CPB Clauss
fibrinogen1.5 g/l of 0.99 and a specificity for post-CPB Clauss fibrinogen >2.0 g/l of 0.83.
doi:10.1371/journal.pone.0126692.g005
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At the time of the study, fibrinogen concentrate was released by our Department of Hema-
tology for perioperative replacement exclusively after documentation of post-CPB fibrinogen
levels (Clauss) of 1.0 g/l or less, in accordance with 2006 ASA guidelines.[38] Applying the de-
cision rule derived from this study, 40% of our patients would have received exogenous fibrino-
gen substitution based on an A1010 mm on-CPB. Instead, in our cohort, post-CPB
fibrinogen assessment was followed by significant use of fresh frozen plasma, platelets and an
overall high exposure to allogeneic transfusion in our study population. This is a likely explana-
tion why postoperative chest tube drainage did not differ between subsets of patients with on-
CPB A1010 mm and A10>10 mm (p = 0.34 for chest tube drainage loss after 24 hours).
Whether early FIBTEM-guided administration of fibrinogen concentrate in above 40% of pa-
tients at risk would have resulted in a reduction of blood loss and allogeneic transfusion expo-
sure, is to be clarified by further studies.
Low levels of plasma fibrinogen appear associated with excessive blood loss and poor patient
outcome after cardiac surgery.[4,7–9,14,21,44,45] It has been also demonstrated that after ter-
mination of CPB, plasma fibrinogen levels reach an individual nadir and tend to recover until
24 hours postoperatively.[8,13,46,47] Taken together, hemostasis in the early post-CPB period
may be compromised substantially by abnormally low plasma fibrinogen, with consequences
like excessive or protracted blood loss, impaired exposure during surgical hemostasis, pro-
longed systemic hypoperfusion, hemodilution, ionized hypocalcaemia, hypothermia and lactic
acidosis. Compensatory use of vasopressors, inotropes and allogeneic blood products are asso-
ciated with, or may be even causative for increased perioperative morbidity and mortality. De-
spite the well-documented importance of sufficient plasma fibrinogen levels in the immediate
post-CPB period, there are still conflicting recommendations about suitable trigger levels for fi-
brinogen substitution.[21–23]. A plasma level of 0.8–1 g/l is nowadays regarded as a too low a
trigger for exogenous fibrinogen replacement.[9,10] On the other end of the spectrum, a fibrin-
ogen target of>3.0 g/l, as suggested by some authors,[16] does not produce supranormal
ROTEM parameters in vitro.[22] It may even cause harm in vivo by promoting thromboembol-
ic cardiovascular events and increasing medical cost.[16,27,48] At present, a target range of
1.5–2.0 g/l for fibrinogen substitution during coagulopathic bleeding is recommended.[8,17,
23,38, 49–51]
Cardiac surgery is characterized by acute, but usually foreseeable and often iatrogenic per-
turbations of the coagulation system by anticoagulants, hemodilution, surface activation and
hypothermia. Thus, early prediction of post-CPB fibrinogen status is an appealing idea. So far,
this approach has been neglected in favor of prophylactic indiscriminate use of antifibrinoly-
tics, and of labor-intensive point-of-care testing.[52] Only recently, Engberink et al. prospec-
tively investigated the diagnostic value of early ROTEM amplitudes for thrombocytopenia and
hypofibrinogenemia in cardiac surgery.[53] They found that FIBTEM-A5, providing results
after 5 min of initialization, closely correlates to A10 (r = 1.00), MCF (r = 0.99) and Clauss fi-
brinogen (r = 0.87). Correlation between simultaneously sampled FIBTEM and fibrinogen data
in this study is very similar to our results. By replacing A10 with A5, the authors were able to
estimate concomitant fibrinogen levels 5 minutes earlier with similar diagnostic accuracy. Gör-
linger et al. confirmed the good correlation of early FIBTEM variables (A5, A10, A15) with
MCF in non-cardiac procedures.[18] When comparing Clauss fibrinogen test performance be-
tween different laboratories, Solomon et al. found no change in plasma fibrinogen when mea-
sured before and after CPB weaning (varying from -0.17 to 0.13, depending on center) and
hypothesized that Clauss measurements on CPB could allow early estimation of fibrinogen def-
icit after weaning.[54]
Our study confirms this hypothesis in a representative cardiac surgical population with a
variable degree of acquired hypofibrinogenemia. However, even if performed by certified lab
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technicians, pre-weaning estimation of post-protamine fibrinogen parameters lacks precision,
according to Bland-Altman analysis of our data. We therefore propose to omit the idea of point-
to-point prediction in favor of a categorical approach. Our results show that Clauss fibrinogen,
FIBTEM parameters, or the combination of both, when sampled on CPB, allow accurate and
clinically useful identification of patients who will be below or within a target zone of 1.5–2.0 g/l
plasma fibrinogen after weaning and heparin reversal. In our study, an A1010 mm on CPB clas-
sified a patient either as hypofibrinogenemic (99% sensitivity for1.5 g/l) or within the substitu-
tion range (83% specificity for<2.0 g/l) following heparin reversal. This allows timely preparation
of fibrinogen replacement for patients bleeding non-surgically after CPB, but avoids overtreat-
ment with fibrinogen concentrate, particularly so when bleeding can be stopped surgically.
Our observational study has several limitations. Data come from a single center and from a
heterogeneous group of patients. This heterogeneity of the cohort with only few patients in
some of the subgroups (e.g. isolated CABG, thoracoabdominal aorta repair) may be seen as dis-
advantage. However, this composition of surgical therapies reflects a realistic clinical spectrum
for university-based cardiac surgical services. Thus, we believe that the heterogeneity of our
study cohort adds to external validity of our decision strategy for fibrinogen substitution. Still,
prediction accuracy and decision thresholds may vary depending on center, laboratory, Clauss
assay, ROTEM operator, but also for different patient populations, surgical and perfusion tech-
niques. [54] For instance, the Multifibren U reagent used in our Clauss analysis is known to be
potentially sensitive to the high heparin levels (>2 IU/ml) routinely used on CPB.[54,55] This,
or alternatively hemoconcentration at the end of the CPB run, might explain the numerical,
though insignificant, increase in post-CPB fibrinogen observed by us and others.[54,55] Also,
the exact time point of paired sampling prior to CPB weaning, and hence, heparin concentra-
tion in the circuit, could not be strictly standardized in relation to the termination of the CPB
run. Such potential confounders are an argument to prefer, on-CPB prior to weaning, a FIB-
TEM-based predictor instead. Finally, perioperative use of hydroxyethyl starch varied some-
what depending on CPB type used (ECC, MECC). This may have affected both fibrinogen and
FIBTEM test accuracy [56–58], i.e., by causing overestimation of fibrinogen in Clauss testing,
and underestimation of true activity by FIBTEM amplitudes, thus contributing to imprecision
of FIBTEM-derived post-CPB fibrinogen estimates.[56–58] Overall however, the dose of col-
loid in our series was much lower than reported in comparable studies (Table 2).[59,60] Since
hydroxyethyl starch is about to disappear as a confounder of intraoperative coagulation testing,
predictive accuracy may improve in future analyses.
In conclusion, our study describes a clinically useful decision approach for early prediction
of post-CPB fibrinogen status from thrombelastometry obtained on CPB prior to weaning. It
allows clinicians a timely and accurate identification of patients who will, after weaning and
heparin reversal, present with plasma fibrinogen below or within the range of 1.5–2.0 g/l rec-
ommended as substitution target by current guidelines.
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